Innoviva has moved a step closer to bringing the first novel antibiotic to market for gonorrhoea in decades after reporting positive results in a phase 3 trial.
An oral dose of zoliflodacin – vying to become the first in the new class of bacterial type II topoisomerase inhibitors – was found to be as effective as the standard regimen of injectable ceftriaxone and oral azithromycin in resolving uncomplicated Neisseria gonorrhoeae infections.
